Biosimilar Newsletter Archive
-
06.23.22 -- EMA Accepts Sandoz's Proposed High Concentration Formulation of Humira Biosimilar
6/23/2022
06/23/22 Biosimilar Development Newsletter
-
06.16.22 -- Key Considerations In Early-Stage Biopharma Financing
6/16/2022
06/16/22 Biosimilar Development Newsletter
-
06.13.22 -- Patient-Centric Drug Delivery Focused On Quality And Regulatory Standards
6/13/2022
06/13/22 Biosimilar Development Newsletter
-
06.13.22 -- Mechanistic Chromatography Modeling For Smarter Process Development
6/13/2022
06/13/22 Biosimilar Development Newsletter
-
06.10.22 -- De-Risking Combination Product Development For Biosimilars
6/10/2022
06/10/22 Biosimilar Development Newsletter
-
06.09.22 -- New Episodes for You: Live Biologics & The Microbiome, Inside CAR-T Therapy for Ovarian Cancer and more.
6/9/2022
06/09/22 Biosimilar Development Newsletter
-
06.09.22 -- Sandoz Announces New Global Act4Biosimilars Initiative
6/9/2022
06/09/22 Biosimilar Development Newsletter
-
06.02.22 -- The Single-Use Bioprocessing Bottleneck: Looking Ahead
6/2/2022
06/02/22 Biosimilar Development Newsletter
-
05.26.22 -- A Better Path For CMO Relationships
5/26/2022
05/26/22 Biosimilar Development Newsletter
-
05.25.22 -- Key Considerations To Drive Bioprocess Innovation
5/25/2022
05/25/22 Biosimilar Development Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more